EPIZYME INC's ticker is EPZM and the CUSIP is 29428V104. A total of 121 filers reported holding EPIZYME INC in Q1 2022. The put-call ratio across all filers is 4.45 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $273,886 | -86.6% | 238,162 | -70.9% | 0.00% | – |
| Q4 2021 | $2,047,000 | -46.4% | 818,853 | +9.7% | 0.00% | -100.0% |
| Q3 2021 | $3,821,000 | -38.4% | 746,378 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $6,202,000 | -21.4% | 746,378 | -17.6% | 0.00% | -50.0% |
| Q1 2021 | $7,887,000 | -30.4% | 905,565 | -13.2% | 0.00% | -33.3% |
| Q4 2020 | $11,335,000 | -20.9% | 1,043,707 | -13.1% | 0.00% | -25.0% |
| Q3 2020 | $14,323,000 | -31.1% | 1,200,566 | -7.2% | 0.00% | -33.3% |
| Q2 2020 | $20,781,000 | -0.2% | 1,293,986 | -3.6% | 0.01% | -14.3% |
| Q1 2020 | $20,828,000 | -4.4% | 1,342,904 | +51.6% | 0.01% | +16.7% |
| Q4 2019 | $21,786,000 | +138.5% | 885,617 | 0.0% | 0.01% | +100.0% |
| Q3 2019 | $9,135,000 | -17.8% | 885,617 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $11,114,000 | -20.7% | 885,617 | -21.7% | 0.00% | -40.0% |
| Q1 2019 | $14,009,000 | +101.1% | 1,130,694 | 0.0% | 0.01% | +66.7% |
| Q4 2018 | $6,965,000 | -41.9% | 1,130,694 | 0.0% | 0.00% | -25.0% |
| Q3 2018 | $11,985,000 | +9.5% | 1,130,694 | +40.0% | 0.00% | 0.0% |
| Q2 2018 | $10,945,000 | -9.5% | 807,776 | +18.5% | 0.00% | 0.0% |
| Q1 2018 | $12,098,000 | -10.8% | 681,594 | -36.9% | 0.00% | -20.0% |
| Q4 2017 | $13,567,000 | -39.7% | 1,081,002 | -8.4% | 0.01% | -44.4% |
| Q3 2017 | $22,489,000 | +26.2% | 1,180,504 | 0.0% | 0.01% | +28.6% |
| Q2 2017 | $17,826,000 | +68.0% | 1,180,504 | +90.8% | 0.01% | +75.0% |
| Q1 2017 | $10,609,000 | +78.0% | 618,591 | +25.6% | 0.00% | +33.3% |
| Q4 2016 | $5,961,000 | +28.7% | 492,631 | 0.0% | 0.00% | +50.0% |
| Q3 2016 | $4,630,000 | -8.2% | 492,631 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $5,045,000 | -15.5% | 492,631 | 0.0% | 0.00% | -33.3% |
| Q1 2016 | $5,971,000 | -13.9% | 492,631 | +13.9% | 0.00% | 0.0% |
| Q4 2015 | $6,931,000 | +24.6% | 432,631 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $5,564,000 | -46.3% | 432,631 | +0.3% | 0.00% | -40.0% |
| Q2 2015 | $10,353,000 | +27.8% | 431,395 | 0.0% | 0.01% | +25.0% |
| Q1 2015 | $8,102,000 | +29.6% | 431,395 | +30.2% | 0.00% | +33.3% |
| Q4 2014 | $6,250,000 | – | 331,224 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 31,833,334 | $47,750,000 | 19.42% |
| MPM BioImpact LLC | 3,425,202 | $3,939,000 | 1.06% |
| Palo Alto Investors LP | 6,774,541 | $7,791,000 | 0.60% |
| Foresite Capital Management I, LLC | 143,759 | $165,000 | 0.29% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 6,603,870 | $7,594,000 | 0.23% |
| Rock Springs Capital Management LP | 7,267,696 | $8,358,000 | 0.21% |
| BP PLC | 24,687 | $28,000 | 0.16% |
| NewGen Asset Management Ltd | 250,000 | $288,000 | 0.13% |
| GSA CAPITAL PARTNERS LLP | 467,836 | $538,000 | 0.07% |
| Frazier Life Sciences Management, L.P. | 739,369 | $850,000 | 0.07% |